

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: *Fu et al.*

Application No. 09/645,456

Filed: August 24, 2000

Confirmation No. 4376

For: GERMINAL CENTER KINASE CELL
CYCLE PROTEINS, COMPOSITIONS
AND METHODS OF USE

FILED VIA EFS

Examiner: Robert Landsman, Ph.D.

Art Unit: 1633

Attorney Reference No. 7946-79811-04

**POWER OF ATTORNEY BY ASSIGNEE (REVOCATION OF PRIOR POWERS) AND
CHANGE OF CORRESPONDENCE ADDRESS**

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

As assignee of record (Reel 011717, Frame 0634-0637, recorded on April 16, 2001; and Reel 013495, Frame 0408-0414, recorded on November 14, 2002) of the entire interest of the application referenced above, all powers of attorney previously given are hereby revoked. The practitioners associated with **Customer Number 74839** are hereby appointed to transact all business in the U.S. Patent and Trademark Office connected with the referenced application, and all continuations and divisions thereof.

Please address all future correspondence to the address associated with **Customer Number 74839**, which address is: Klarquist Sparkman, LLP, 121 S.W. Salmon Street, Suite 1600, Portland, OR 97204

Address all telephone calls to Karri Kuenzli Bradley, Ph.D. at telephone number (503) 595-5300. Please update the Attorney Reference No. for this application to 7946-79811-04.

The undersigned is authorized to sign this Power of Attorney by Assignee on behalf of the assignee.


Executed at South San Francisco, California on the 17 day of December 2007.

Rigel Pharmaceuticals, Inc.

By

Name

Title


James J. Diehl
Executive Director of Intellectual Property and
Associate Gen. Counsel